Non-Hodgkin Lymphoma | Specialty

PI3K-Targeted Therapy for R/R Follicular Lymphoma

July 24th 2018

R/R Follicular Lymphoma: Second and Third-Line Options

July 24th 2018

Timing of Second-Line Therapy in Follicular Lymphoma

July 24th 2018

Maintenance Therapy Outcomes in Follicular Lymphoma

July 24th 2018

Follicular Lymphoma: Results from Phase II GALLIUM Study

July 24th 2018

Immunochemotherapy Approaches for Follicular Lymphoma

July 24th 2018

Risk Classification and Assessment in Follicular Lymphoma

July 24th 2018

Follicular Lymphoma Diagnostic Workup

July 24th 2018

Ibrutinib/Rituximab Emerges as New Standard in Waldenstrom Macroglobulinemia

July 23rd 2018

Results from the phase III iNNOVATE trial established the combination of ibrutinib plus rituximab as the new standard of care in Waldenström macroglobulinemia.

Dr. Vose Discusses the Importance of Genomic Analysis in NHL

July 18th 2018

Julie M. Vose, MD, MBA, professor, internal medicine, chief, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the importance of genomic analysis in patients with non-Hodgkin lymphoma.

Navigating the Toxicities of Novel-Novel Combinations in Lymphoma

July 18th 2018

Combinations of novel drugs in lymphomas have the potential to overcome resistance to therapy but come with sometimes unexpected adverse events that demand careful monitoring.

CAR T-cell Therapies Offer Hope for DLBCL

July 15th 2018

Chimeric antigen receptor T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell lymphoma, with research now exploring ways to shift these agents earlier in the treatment paradigm.

Frontline Ibrutinib Plus R-CHOP Misses Primary Endpoint in Phase III DLBCL Trial

July 11th 2018

Combining ibrutinib with standard R-CHOP did not improve event-free survival versus R-CHOP alone in the first-line setting for patients with diffuse large B-cell lymphoma.

Dr. Flinn on CAR T-Cell Therapy in Non-Hodgkin Lymphoma

July 11th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

PFS Valid Surrogate Endpoint for Overall Survival in Frontline DLBCL

July 11th 2018

Progression-free survival appears to be a surrogate endpoint for overall survival in patients undergoing first-line treatment for diffuse large B-cell lymphoma, according to results from a large pooled analysis.

Dr. Abramson Discusses Lisocabtagene Maraleucel in NHL

July 10th 2018

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses lisocabtagene maraleucel (JCAR017; liso-cel) as a treatment for patients with non-Hodgkin lymphoma.

Pixantrone Falls Short in Phase III B-Cell NHL Trial

July 9th 2018

Combining pixantrone (Pixuvri) with rituximab (Rituxan) failed to improve progression-free survival compared with gemcitabine plus rituximab in patients with aggressive B-cell non-Hodgkin lymphoma.

Axicabtagene Ciloleucel Approaches EU Approval for DLBCL, PMBCL

June 29th 2018

The European Medicines Agency’s CHMP has recommended approval of axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.

Tisagenlecleucel Nears European Approval for DLBCL, ALL

June 29th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of tisagenlecleucel for the treatment of either adult patients with diffuse large B-cell lymphoma that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse posttransplant, or in second or later relapse.

FDA Grants Ibrutinib/Rituximab Priority Review for Waldenstrom Macroglobulinemia

June 25th 2018

The FDA has granted a priority review to a supplemental new drug application for ibrutinib for use in combination with rituximab as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.